精准医学时代的胰腺癌早期检测
综述讨论精准医学时代胰腺导管腺癌早期检测的多层面策略,包括高危人群靶向筛查、血清生物标志物与「液体活检」、人工智能辅助的影像学肿瘤检测。
要点
- 高危人群靶向筛查是胰腺导管腺癌早期检测策略之一。
- 血清生物标志物与「液体活检」用于早期检测。
- 人工智能辅助影像学检查的肿瘤检测用于早期发现。
核心结论
- 精准医学时代胰腺导管腺癌早期检测采用多层面策略,包括高危人群靶向筛查、血清生物标志物与「液体活检」、人工智能辅助的影像学肿瘤检测。
研究设计与样本
- 综述;检索范围与纳入文献原文未报告。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality and it is often diagnosed at advanced stages due to non-specific clinical presentation. Disease detection at localized disease stage followed by surgical resection remains the only potentially curative treatment. In this era of precision medicine, a multifaceted approach to early detection of PDAC includes targeted screening in high-risk populations, serum biomarkers and "liquid biopsies", and artificial intelligence augmented tumor detection from radiologic examinations. In this review, we will review these emerging techniques in the early detection of PDAC.
引用
- Ahmed TM, Kawamoto S, Lopez-Ramirez F, et al. Early detection of pancreatic cancer in the era of precision medicine. Abdom Radiol (NY). 2024. PMID: 38761272. doi:10.1007/s00261-024-04358-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。